Worldwide News

GW Pharmaceuticals reports that Sativex has received regulatory approval in Austria as a treatment of spasticity due to Multiple Sclerosis (MS). The launch of Sativex in Austria is expected to take place during 2012 following completion of the national pricing and reimbursement process.